EQ Stock Overview

A clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More details

EQ fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 14.8% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($14M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Equillium, Inc. Competitors

Carisma Therapeutics

NasdaqGM:CARM

US$13.8m

BioRestorative Therapies

NasdaqCM:BRTX

US$12.5m

HOOKIPA Pharma

NasdaqCM:HOOK

US$14.8m

Bolt Biotherapeutics

NasdaqCM:BOLT

US$16.3m

Price History & Performance

Summary of share price highs, lows and changes for Equillium
Historical stock prices
Current Share Price	US$0.39
52 Week High	US$2.43
52 Week Low	US$0.37
Beta	1.87
1 Month Change	-48.65%
3 Month Change	-47.57%
1 Year Change	-81.41%
3 Year Change	-87.93%
5 Year Change	-83.62%
Change since IPO	-97.20%

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Mar 31

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Feb 12

Recent updates

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Mar 31

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Feb 12

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Nov 16

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Aug 12

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

May 03

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Mar 26

Equillium GAAP EPS of -$0.41 in-line

Aug 15

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Oct 08

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Mar 09

Equillium prices $30M registered direct offering

Feb 04

Equillium (EQ) Investor Presentation - Slideshow

Dec 04

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Nov 24

Shareholder Returns

	EQ	US Biotechs	US Market
7D	-52.2%	-2.3%	-3.5%
1Y	-81.4%	-8.9%	5.8%

Return vs Industry: EQ underperformed the US Biotechs industry which returned -8.9% over the past year.

Return vs Market: EQ underperformed the US Market which returned 5.8% over the past year.

Price Volatility

Is EQ's price volatile compared to industry and market?
EQ volatility
EQ Average Weekly Movement	18.1%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.5%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.3%

Stable Share Price: EQ's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EQ's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2017	45	Bruce Steel	www.equilliumbio.com

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.

Equillium, Inc. Fundamentals Summary

How do Equillium's earnings and revenue compare to its market cap?
EQ fundamental statistics
Market cap	US$14.36m
Earnings (TTM)	-US$8.07m
Revenue (TTM)	US$41.10m

0.3x

P/S Ratio

-1.7x

P/E Ratio

Is EQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EQ income statement (TTM)
Revenue	US$41.10m
Cost of Revenue	US$0
Gross Profit	US$41.10m
Other Expenses	US$49.16m
Earnings	-US$8.07m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.23
Gross Margin	100.00%
Net Profit Margin	-19.63%
Debt/Equity Ratio	0%

How did EQ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/31 21:45
End of Day Share Price	2025/03/31 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Equillium, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	H.C. Wainwright & Co.
Biren Amin	Jefferies LLC
Catherine Novack	JonesTrading Institutional Services, LLC

EQ Stock Overview

Rewards

Risk Analysis

Equillium, Inc. Competitors

NasdaqGM:CARM

US$13.8m

NasdaqCM:BRTX

US$12.5m

NasdaqCM:HOOK

US$14.8m

NasdaqCM:BOLT

US$16.3m

Price History & Performance

Recent News & Updates

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Equillium, Inc., Annual General Meeting, May 21, 2025

New major risk - Share price stability

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Recent updates

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Equillium, Inc., Annual General Meeting, May 21, 2025

New major risk - Share price stability

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Consensus EPS estimates fall by 232%

Equillium and Biocon Limited Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

High number of new directors

Equillium, Inc. Announces Board and Committee Changes

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

New major risk - Financial position

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Price target decreased by 49% to US$3.33

Consensus revenue estimates fall by 27%

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Financial position

New major risk - Share price stability

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Price target increased by 9.5% to US$6.75

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

Consensus EPS estimates fall by 188%

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

New major risk - Share price stability

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New minor risk - Share price stability

Price target decreased by 10% to US$6.17

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Consensus revenue estimates increase by 187%

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Consensus revenue estimates increase by 17%

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Price target decreased to US$12.00

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Price target decreased to US$12.00

Price target increased to US$14.00

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab